• English
    • français
  • Help
  •  | 
  • Contact
  •  | 
  • About
  •  | 
  • Login
  • HAL portal
  •  | 
  • Pages Pro
  • EN
  •  / 
  • FR
View Item 
  •   LillOA Home
  • Liste des unités
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
  • View Item
  •   LillOA Home
  • Liste des unités
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Investigation of the Redox Behavior of ...
  • BibTeX
  • CSV
  • Excel
  • RIS

Document type :
Article dans une revue scientifique
DOI :
10.1021/mp800007x
Permalink :
http://hdl.handle.net/20.500.12210/55867
Title :
Investigation of the Redox Behavior of Ferroquine, a New Antimalarial
Author(s) :
Chavain, Natascha [Auteur]
Unité de Catalyse et Chimie du Solide - UMR 8181 [UCCS]
Vezin, Herve [Auteur] refId
Laboratoire de Chimie Organique et Macromoleculaire [UMR CNRS 8009]
Dive, Daniel [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Touati, Nadia [Auteur]
Laboratoire de Chimie Organique et Macromoleculaire [UMR CNRS 8009]
Paul, Jean-Francois [Auteur] refId
Unité de Catalyse et Chimie du Solide - UMR 8181 [UCCS]
Buisine, Eric [Auteur]
Laboratoire de Chimie Organique et Macromoleculaire [UMR CNRS 8009]
Biot, Christophe [Auteur] refId
Unité de Catalyse et Chimie du Solide - UMR 8181 [UCCS]
Journal title :
Molecular pharmaceutics
Pages :
710-716
Publisher :
American Chemical Society
Publication date :
2008-06-19
ISSN :
1543-8384
English keyword(s) :
Hydroxyls
Redox reactions
Parasites
Sandwich compounds
Quantum mechanics
HAL domain(s) :
Chimie/Chimie théorique et/ou physique
English abstract : [en]
Ferroquine (FQ or SR97193) is a unique ferrocene antimalarial drug candidate which just entered phase IIb clinical trials in autumn 2007. FQ is able to overcome the chloroquine (CQ) resistance problem, an important limit ...
Show more >
Ferroquine (FQ or SR97193) is a unique ferrocene antimalarial drug candidate which just entered phase IIb clinical trials in autumn 2007. FQ is able to overcome the chloroquine (CQ) resistance problem, an important limit to the control of Plasmodium falciparum, the principal causative agent of malaria. However, as for other therapeutic agents such as chloroquine (CQ) and artemisin, its mechanism of action remains partially unknown. Most investigations have so far focused on comparing the activity of FQ to that of CQ in order to understand how the ferrocene core contributes to a stronger antiplasmodial activity. Studies have already shown that the ferrocene altered the shape, volume, lipophilicity, basicity and also electronic profile of the parent molecule and, hence, its pharmacodynamic behavior. However, few investigations have been undertaken to probe the real contribution of redox properties of the ferrocene (iron(II))/ferricinium (iron(III)) system in FQ as reported in this article. In our experimental and theoretical approach, we considered the redox profile of the ferrocene core of FQ in the specific conditions (acidic and oxidizing) of the parasitic digestive vacuole as a possible discriminating property from CQ in the antimalarial activity.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Collections :
  • Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Source :
Harvested from HAL
Submission date :
2021-10-10T01:30:44Z
Université de Lille

Mentions légales
Université de Lille © 2017